去势抵抗性前列腺癌的药物治疗现状

doi:10.11904/j.issn.1002-3070.2021.04.015

Abstract

Abstract: Androgen deprivation therapy(ADT)has always been a representative therapy for advanced prostate cancer.When prostate cancer progresses to castration resistant prostate cancer(CRPC),ADT resistance also emerges.Currently,docetaxel is the first cytotoxic chemotherapy drug approved for CRPC.In addition,abiraterone,enzalutamide and other drugs have also been approved by FDA,and these drugs have shown good survival benefits.In this article,we reviewed the clinical trials and survival benefits of these therapies,and discussed emerging drugs in this field.This review will describe the current status of CRPC drug treatment and provide references for clinical medication.

Key words: Prostate cancer, Castration-resistant prostate cancer(CRPC), Drug therapy

CLC Number:

R737.25

GAO Ke, REN Minghua. Current status of drug therapy for castration-resistant prostate cancer[J]. Journal of Practical Oncology, 2021, 35(4): 376-379.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2021.04.015

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2021/V35/I4/376

References

1 Miller KD,Nogueira L,Mariotto AB,et al.Cancer treatment and survivorship statistics[J].CA Cancer J Clin,2019,69(5):363-385.
2 Teoh JYC,Hirai HW,Ho JMW,et al.Global incidence of prostate cancer in developing and developed countries with changing age structures[J].PLoS One,2019,14(10):e0221775.
3 Rasool RU,Natesan R,Deng Q,et al.CDK7 inhibition suppresses castration-resistant prostate cancer through MED1 inactivation[J].Cancer Discov,2019,9(11):1538-1555.
4 Yu J,Sun L,Hao T,et al.Restoration of FKBP51 protein promotes the progression of castration resistant prostate cancer[J].Ann Transl Med,2019,7(23):729.
5 Dong L,Zieren RC,Xue W,et al.Metastatic prostate cancer remains incurable,why?[J].Asian J Urol,2019,6(1):26-41.
6 中国抗癌协会泌尿肿瘤专业委员会.中国去势抵抗性前列腺癌诊治专家共识[J].中华外科杂志,2016,54(7):481-484.
7 Mohler JL,Antonarakis ES,Armstrong AJ,et al.Prostate cancer,version 2.2019,NCCN clinical practice guidelines in oncology[J].J Natl Compr Canc Netw,2019,17(5):479-505.
8 James A,Vincent B,Sivadas A,et al.A study on the clinical outcome of abiraterone acetate in castration resistant prostate cancer patients[J].Int J Hematol Oncol Stem Cell Res,2018,12(1):4-7.
9 Yuan F,Hankey W,Wu D,et al.Molecular determinants for enzalutamide-induced transcription in prostate cancer[J].Nucleic Acids Res,2019,47(19):10104-10114.
10 Hussain M,Fizazi K,Saad F,et al.Enzalutamide in men with non-metastatic,castration-resistant prostate cancer[J].N Engl J Med,2018,378(26):2465-2474.
11 David L,Joaquin M,Raquel PL,et al.Sequencing of agents in castration-resistant prostate cancer[J].Lancet Oncology,2015,16(6):279-292.
12 Markham A,Duggan S.Darolutamide:first approval[J].Drugs,2019,79(16):1813-1818.
13 Zurth C,Sandmann S,Trummel D,et al.Blood-brain barrier penetration of [14C] darolutamide compared with [14C] enzalutamide in rats using whole body autoradiography[J].J Clin Oncol,2018,36(Suppl 6S):345.
14 Saad F,Aprikian A,Finelli A,et al.2019 Canadian Urological Association(CUA)-Canadian Uro Oncology Group(CUOG)guideline:management of castration-resistant prostate cancer(CRPC)[J].Can Urol Assoc J,2019,13(10):307-314.
15 He D,Sun Z,Guo J,et al.A multicenter observational study of the real-world use of docetaxel for metastatic castration-resistant prostate cancer in China[J].Asia Pac J Clin Oncol,2019,15(3):144-150.
16 Al-Mansouri L,Gurney H.Clinical concepts for cabazitaxel in the management of metastatic castration-resistant prostate cancer[J].Asia Pac J Clin Oncol,2019,15(6):288-295.
17 Komura K,Sweeney CJ,Inamoto T,et al.Current treatment strategies for advanced prostate cancer[J].Int J Urol,2018,25(3):220-231.
18 Higano CS,Armstrong AJ,Sartor AO,et al.Real-world outcomes of sipuleucel-T treatment in PROCEED,a prospective registry of men with metastatic castration-resistant prostate cancer[J].Cancer,2019,125(23):4172-4180.
19 Antonarakis ES,Piulats JM,Gross-Goupil M,et al.Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer:multicohort,open-label phase II KEYNOTE-199 study[J].J Clin Oncol,2020,38(5):395-405.
20 Kumar A,Dhar S,Campanelli G,et al.MTA1 drives malignant progression and bone metastasis in prostate cancer[J].Mol Oncol,2018,12(9):1596-1607.
21 Gallicchio R,Mastrangelo PA,Nardelli A,et al.Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer:when and why[J].Tumori,2019,105(5):367-377.
22 Rizzini EL,Dionisi V,Ghedini P,et al.Clinical aspects of mCRPC management in patients treated with radium-223[J].Sci Rep,2020,10(1):6681.
23 Baba K,Kaida H,Hattori C,et al.Tumoricidal effect and pain relief after concurrent therapy by strontium-89 chloride and zoledronic acid for bone metastases[J].Hell J Nucl Med,2018,21(1):15-23.
24 Zakaly HMH,Mostafa MYA,Deryabina D,et al.Comparative studies on the potential use of 177Lu-based radiopharmaceuticals for the palliative therapy of bone metastases[J].Int J Radiat Biol,2020,96(6):779-789.
25 武俊平,陈婷婷,宋文华,等.康艾注射液联合多西他赛及泼尼松治疗骨转移激素抵抗性前列腺癌的疗效观察[J].空军医学杂志,2018,34(2):115-118.
26 陈浩然,刘浩.中医药防治去势抵抗性前列腺癌的思路与方法[J].中华中医药学刊,2021,39(3):164-168.
27 Tuguzbaeva G,Yue E,Chen X,et al.PEP06 polypeptide 30 is a novel cluster-dissociating agent inhibiting αv integrin/FAK/Src signaling in oral squamous cell carcinoma cells[J].Acta Pharm Sin B,2019,9(6):1163-1173.
28 Yu S,Li L,Tian W,et al.PEP06 polypeptide 30 exerts antitumour effect in colorectal carcinoma via inhibiting epithelial-mesenchymal transition[J].Br J Pharmacol,2018,175(15):3111-3130.
29 Martellucci S,Clementi L,Sabetta S,et al.Src family kinases as therapeutic targets in advanced solid tumors:what we have learned so far[J].Cancers(Basel),2020,12(6):1448.
30 Hwang S,Takimoto T,Hemler ME.Integrin-independent support of cancer drug resistance by tetraspanin CD151[J].Cell Mol Life Sci,2019,76(8):1595-1604.
31 De Felice F,Tombolini V,Marampon F,et al.Defective DNA repair mechanisms in prostate cancer:impact of olaparib[J].Drug Des Devel Ther,2017,11:547-552.
32 Robinson D,Van Allen EM,Wu YM,et al.Integrative clinical genomics of advanced prostate cancer[J].Cell,2015,161(5):1215-1228.
33 Hussain M,Mateo J,Fizazi K,et al.PROfound:Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer(mCRPC)with homologous recombination repair(HRR)gene alterations[J].Ann Oncol,2019,30:881-882.
34 包乐,唐丽萍.EphB6受体在恶性肿瘤中的研究进展[J].实用肿瘤学杂志,2020,34(1):83-87.

[1]	MIAO Pengcheng, KANG Yindong, LI Fudong, MENG Dongdong, WANG Dongxing, CHANG Dehui. Research progress of lncRNA SNHGs in the occurrence and development of prostate cancer [J]. Journal of Practical Oncology, 2020, 34(5): 446-450.
[2]	JIANG Tao,ZHANG Xu. The research progress of orphan nuclear receptors in prostate cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 377-380.
[3]	LI Jiebing,ZHANG Yanhua,YANG Hongyan,ZHANG Cui,LI Bo,CHENG Wen. Development of prostate cancer risk in patients with chronic prostate inflammation and wHGPIN during puncture rebiopsy [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(3): 217-221.
[4]	MAO Gaocai,ZHU Qicong,SHEN Hongfeng,TU Ruisha,YAN Qingguo. The clinicopathology analysis of three cases of carcinoma with multi-directional differentiation derived from junction of bladder and prostate [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(6): 538-542.
[5]	LU Ying,HUANG Haixin,LI Guisheng. GEMOX regimen in treatment of relapsed or refractory non-Hodgkin′s lymphoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2011, 25(6): 547-550.

Current status of drug therapy for castration-resistant prostate cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 5

Recommended Articles

Metrics

Comments